Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2025-12-30 @ 3:02 PM
Study NCT ID:
NCT00540956
Status:
COMPLETED
Last Update Posted:
2011-05-16
First Post:
2007-10-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
Sponsor:
Institut Paoli-Calmettes
Organization:
Study Overview
Official Title:
Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
Detailed Description:
OBJECTIVES:
Primary
* Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
Secondary
* Measure the kinetics of cytotoxic functional recovery of NK cells.
* Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
Primary
* Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
Secondary
* Measure the kinetics of cytotoxic functional recovery of NK cells.
* Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: